Last updated on July 2016

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Brief description of study

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

Clinical Study Identifier: NCT02851589


Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Lin Yang, Ph.D.

PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Suzhou, China
  Connect »